KALA BIO, Inc. Files 8-K on Executive Changes and Financials
Ticker: KALA · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1479419
| Field | Detail |
|---|---|
| Company | Kala Bio, INC. (KALA) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $655,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, financial-reporting
TL;DR
KALA BIO filed an 8-K detailing executive changes and financial exhibits.
AI Summary
KALA BIO, Inc. filed an 8-K on August 29, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing provides updates on the company's leadership and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine 8-K filing reporting on corporate governance and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- KALA BIO, Inc. (company) — Registrant
- August 29, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 1167 Massachusetts Avenue (address) — Principal Executive Offices
- Arlington, MA (location) — City and State of Principal Executive Offices
FAQ
What specific executive positions were affected by the departures or appointments mentioned in the filing?
The filing indicates "Departure of Directors or Certain Officers" and "Appointment of Certain Officers" but does not specify the exact positions in the provided text.
Are there any details about the compensatory arrangements for the officers mentioned?
The filing lists "Compensatory Arrangements of Certain Officers" as an item, but the specific details of these arrangements are not included in the provided text.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This indicates that the company is providing updated financial information and supporting documents as required by the SEC.
When was KALA BIO, Inc. incorporated?
KALA BIO, Inc. was incorporated in Delaware.
What is the primary business of KALA BIO, Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code 2834, KALA BIO, Inc. is in the business of Pharmaceutical Preparations.
Filing Stats: 1,326 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2025-09-02 08:08:53
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share KALA The Nasdaq C
- $655,000 — ll be paid an annualized base salary of $655,000, effective as of the Effective Date, an
Filing Documents
- tm2524756d1_8k.htm (8-K) — 30KB
- tm2524756d1_ex10-1.htm (EX-10.1) — 18KB
- 0001104659-25-086011.txt ( ) — 215KB
- kala-20250829.xsd (EX-101.SCH) — 3KB
- kala-20250829_lab.xml (EX-101.LAB) — 33KB
- kala-20250829_pre.xml (EX-101.PRE) — 22KB
- tm2524756d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 29, 2025, KALA BIO, Inc. (the "Company") appointed Todd Bazemore as the Chief Executive Officer of the Company, effective immediately (the "Effective Date"). As of the Effective Date, Mr. Bazemore also continued to serve as President of the Company and ceased serving as Chief Operating Officer of the Company. Effective as of the Effective Date, Mr. Bazemore was also elected as a Class II director to serve on the Board of Directors of the Company (the "Board") until the Company's 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Mr. Bazemore, age 55, has served as the Company's interim Chief Executive Officer since February 2025, as the Company's President since December 2021 and as the Company's Chief Operating Officer since November 2017. Previously, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc. ("Santhera"), a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp. ("Dyax"), a biopharmaceutical company focused on orphan diseases, between April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax's commercial department including sales, marketing, commercial analytics, market access and patient services. Between April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. ("Sunovion") (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr. Bazemore held several roles of i
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Second Amendment to Offer Letter, dated August 29, 2025, between the Company and Todd Bazemore 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: September 2, 2025 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary